B&K (HKSE:02396) ROE % Adjusted to Book Value: -30.50% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02396 B&K Corp Ltd HKSE:02396
8 GF Score
Price HK$4.40
! 1 Warning Sign
View Full Analysis

What is B&K ROE % Adjusted to Book Value?

B&K HKSE:02396 8 ROE % Adjusted to Book Value is -30.50% as of Dec. 2025. GuruFocus rates HKSE:02396 with a GF Score™ of 8/100. The stock has 1 warning sign investors should review.

B&K's ROE % for the quarter that ended in Dec. 2025 was -84.17%. B&K's PB Ratio for the quarter that ended in Dec. 2025 was 2.76. B&K's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -30.50%.

B&K ROE % Adjusted to Book Value Related Terms

B&K ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for B&K's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

B&K ROE % Adjusted to Book Value Chart

B&K Annual Data
Trend Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 0.00 -19.67

B&K Quarterly Data
Dec23 Dec24 May25 Sep25 Dec25
ROE % Adjusted to Book Value 0.00 0.00 0.00 0.00 -30.50

HKSE:02396 vs VRTX, REGN, MRNA: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, B&K's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

B&K ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, B&K's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where B&K's ROE % Adjusted to Book Value falls into.


HKSE:02396
8GF Score
B&K Corp Ltd HKSE:02396
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

B&K ROE % Adjusted to Book Value Calculation

B&K's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-54.28% / 2.76
=-19.67%

B&K's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-84.17% / 2.76
=-30.50%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -30.50% mean?
B&K (HKSE:02396) has a ROE % Adjusted to Book Value of -30.50% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on B&K and its competitors.
Is B&K's ROE % Adjusted to Book Value too high?
B&K's current ROE % Adjusted to Book Value is -30.50%. Overall, B&K has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does B&K's ROE % Adjusted to Book Value compare to VRTX and REGN?
B&K's ROE % Adjusted to Book Value of -30.50% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on B&K and its competitors. B&K's current ROE % Adjusted to Book Value is -30.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is B&K stock overvalued right now?
B&K (HKSE:02396) has a current ROE % Adjusted to Book Value of -30.50%. The current ROE % Adjusted to Book Value is -30.50%. B&K's overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For B&K (HKSE:02396), the current ROE % Adjusted to Book Value is -30.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

B&K Business Description

Address No. 19 Qinling Road, Xiexin Center, Room 1507, Building 1, Laoshan District, Shandong Province, Qingdao, CHN
B&K Corp Ltd is a China-based biopharmaceutical company committed to developing therapies with an emphasis on protein drugs for indications with medical needs and market opportunities. The company prominently focuses on the discovery, development and commercialization of therapies for wound healing, currently PDGF drugs. Its pipeline consisted of ten candidates, seven of which are PDGF candidates, including two Core Products, namely Pro-101-1 for the treatment of thermal burns and Pro-101-2 for the treatment of DFUs, which are rhPDGF-BB drugs. The company operates in a single reportable segment: the research and development of biopharmaceutical products. Geographically, the company generates all its revenue from Chinese Mainland.
8GF Score

Get the complete analysis for HKSE:02396

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$4.40
Price